S-1-话题@MedSci

#S-1#

72篇内容 | 2671人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1477854, encodeId=86c914e7854a2, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=CLIN CANCER RES：DC-CIK免疫治疗联合S-1化疗治疗晚期胰腺癌, objectType=article, longId=112231, objectId=c53111223176, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c53111223176, replyNumber=0, likeNumber=84, createdTime=2017-09-09, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c53111223176, moduleTitle=CLIN CANCER RES：DC-CIK免疫治疗联合S-1化疗治疗晚期胰腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c53111223176)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477853, encodeId=7a3c14e785369, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=J Thorac Oncol：一文掌握ROS-1阳性肺癌研究进展, objectType=article, longId=111915, objectId=95c8111915ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95c8111915ce, replyNumber=0, likeNumber=69, createdTime=2017-09-06, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95c8111915ce, moduleTitle=J Thorac Oncol：一文掌握ROS-1阳性肺癌研究进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=95c8111915ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477852, encodeId=559314e785261, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=Lancet Oncol:TAS-102 联合贝伐单抗有效治疗难治性转移性结直肠癌, objectType=article, longId=107861, objectId=776510e86195, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=776510e86195, replyNumber=0, likeNumber=77, createdTime=2017-08-07, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=776510e86195, moduleTitle=Lancet Oncol:TAS-102 联合贝伐单抗有效治疗难治性转移性结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=776510e86195)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477851, encodeId=f4a114e7851d2, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=Lancet Oncol：C-TASK FORCE研究：TAS-102 联合贝伐单抗有效治疗难治性转移性结直肠癌, objectType=article, longId=107858, objectId=4df710e8587e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4df710e8587e, replyNumber=0, likeNumber=124, createdTime=2017-08-07, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4df710e8587e, moduleTitle=Lancet Oncol：C-TASK FORCE研究：TAS-102 联合贝伐单抗有效治疗难治性转移性结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4df710e8587e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477850, encodeId=9ed114e78506f, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=Lancet Oncol：TAS-102+贝伐单抗可用于治疗难治性的转移性结直肠癌, objectType=article, longId=107145, objectId=3c8510e145e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c8510e145e7, replyNumber=0, likeNumber=83, createdTime=2017-07-31, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c8510e145e7, moduleTitle=Lancet Oncol：TAS-102+贝伐单抗可用于治疗难治性的转移性结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c8510e145e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477849, encodeId=84e714e784983, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=NLS Pharma称NLS-1治疗成人ADHD患者的二期数据令人鼓舞, objectType=article, longId=101028, objectId=a8721010284d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8721010284d, replyNumber=0, likeNumber=84, createdTime=2017-06-09, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8721010284d, moduleTitle=NLS Pharma称NLS-1治疗成人ADHD患者的二期数据令人鼓舞, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8721010284d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477848, encodeId=6a1514e784800, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=“饿死”癌细胞的药物IACS-10759已进入临床试验阶段, objectType=article, longId=81237, objectId=d0388123e8a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0388123e8a, replyNumber=0, likeNumber=88, createdTime=2016-10-29, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0388123e8a, moduleTitle=“饿死”癌细胞的药物IACS-10759已进入临床试验阶段, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0388123e8a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477847, encodeId=17c014e78470f, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=Lancet Oncol：骨肉瘤：术前化疗效果差，术后要不要加强化疗？(EURAMOS-1), objectType=article, longId=77007, objectId=5eb2e7007fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5eb2e7007fd, replyNumber=0, likeNumber=87, createdTime=2016-09-10, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5eb2e7007fd, moduleTitle=Lancet Oncol：骨肉瘤：术前化疗效果差，术后要不要加强化疗？(EURAMOS-1), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5eb2e7007fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477846, encodeId=b69614e78466b, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=Neurology：缺血性卒中生理功能的检测：PROMIS 优于SIS-16量表, objectType=article, longId=72448, objectId=1163e24486b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1163e24486b, replyNumber=0, likeNumber=69, createdTime=2016-07-12, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1163e24486b, moduleTitle=Neurology：缺血性卒中生理功能的检测：PROMIS 优于SIS-16量表, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1163e24486b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477845, encodeId=b29c14e7845ae, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=Lancet：胰腺癌术后辅助化疗，S-1不劣于吉西他滨, objectType=article, longId=69845, objectId=b02e69845d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b02e69845d9, replyNumber=0, likeNumber=76, createdTime=2016-06-04, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b02e69845d9, moduleTitle=Lancet：胰腺癌术后辅助化疗，S-1不劣于吉西他滨, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b02e69845d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477844, encodeId=9eba14e7844c1, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=Lancet Oncol：可考虑将S-1作为HER2阴性的转移性乳腺癌的一线治疗方法, objectType=article, longId=59361, objectId=aeb75936164, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aeb75936164, replyNumber=0, likeNumber=70, createdTime=2015-11-25, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aeb75936164, moduleTitle=Lancet Oncol：可考虑将S-1作为HER2阴性的转移性乳腺癌的一线治疗方法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aeb75936164)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477843, encodeId=1ce314e784344, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=FDA批准TAS-102(Lonsurf)用于治疗晚期结直肠癌, objectType=article, longId=56824, objectId=8f225682468, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f225682468, replyNumber=0, likeNumber=40, createdTime=2015-10-03, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f225682468, moduleTitle=FDA批准TAS-102(Lonsurf)用于治疗晚期结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f225682468)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477842, encodeId=3a6514e7842e0, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=NEJM：TAS-102对难治性转移性结直肠癌的临床效果, objectType=article, longId=50749, objectId=cb8350e49b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb8350e49b1, replyNumber=0, likeNumber=71, createdTime=2015-05-16, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb8350e49b1, moduleTitle=NEJM：TAS-102对难治性转移性结直肠癌的临床效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb8350e49b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477841, encodeId=865014e78417e, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=ASCO GI 2015：S-1/顺铂可作为晚期胃癌新辅助化疗方案（COMPASS研究）？, objectType=article, longId=45955, objectId=807c4595549, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=807c4595549, replyNumber=0, likeNumber=105, createdTime=2015-01-23, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=807c4595549, moduleTitle=ASCO GI 2015：S-1/顺铂可作为晚期胃癌新辅助化疗方案（COMPASS研究）？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=807c4595549)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477840, encodeId=00af14e784051, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=RECOURSE试验III期：TAS-102对比安慰剂治疗已给予更佳支持治疗且能耐受标准化疗的mCRC患者, objectType=article, longId=43695, objectId=811c4369574, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=811c4369574, replyNumber=0, likeNumber=75, createdTime=2014-12-10, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=811c4369574, moduleTitle=RECOURSE试验III期：TAS-102对比安慰剂治疗已给予更佳支持治疗且能耐受标准化疗的mCRC患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=811c4369574)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477839, encodeId=b9f114e783905, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=CSMO 2014 ：S-1或为晚期非小细胞肺癌治疗新选择, objectType=article, longId=37611, objectId=e0c93e611ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0c93e611ba, replyNumber=0, likeNumber=74, createdTime=2014-07-11, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0c93e611ba, moduleTitle=CSMO 2014 ：S-1或为晚期非小细胞肺癌治疗新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0c93e611ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477838, encodeId=7a2314e783805, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=北山丈二：S-1+DTX治疗腹膜播散胃癌, objectType=article, longId=37363, objectId=82c53e3630b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82c53e3630b, replyNumber=0, likeNumber=69, createdTime=2014-07-05, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82c53e3630b, moduleTitle=北山丈二：S-1+DTX治疗腹膜播散胃癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82c53e3630b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477837, encodeId=fb0e14e78377b, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=TAS-102能提高转移性结肠癌患者的存活率, objectType=article, longId=37287, objectId=139a3e28729, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=139a3e28729, replyNumber=0, likeNumber=59, createdTime=2014-07-04, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=139a3e28729, moduleTitle=TAS-102能提高转移性结肠癌患者的存活率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=139a3e28729)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477832, encodeId=509a14e783203, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=Gynecol Oncol：吉非替尼联合S-1与卡铂一线治疗发生表皮生长因子受体突变的晚期非小细胞肺癌患者的II期临床试验, objectType=article, longId=37047, objectId=6eb73e0471c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6eb73e0471c, replyNumber=0, likeNumber=41, createdTime=2014-06-27, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6eb73e0471c, moduleTitle=Gynecol Oncol：吉非替尼联合S-1与卡铂一线治疗发生表皮生长因子受体突变的晚期非小细胞肺癌患者的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6eb73e0471c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477831, encodeId=0b2a14e783189, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=吉西他滨联合S-1对比吉西他滨联合顺铂治疗晚期胆管癌的随机III期研究：一项日本临床肿瘤研究组的新研究（JCOG1113）, objectType=article, longId=37046, objectId=47363e0462c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47363e0462c, replyNumber=0, likeNumber=73, createdTime=2014-06-27, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47363e0462c, moduleTitle=吉西他滨联合S-1对比吉西他滨联合顺铂治疗晚期胆管癌的随机III期研究：一项日本临床肿瘤研究组的新研究（JCOG1113）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47363e0462c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

S-1

2020-05-29

ms3117646317107274

#S-1#

CLIN CANCER RES：DC-CIK免疫治疗联合S-1化疗治疗晚期胰腺癌

2017-09-09

ms3117646317107274

#S-1#

J Thorac Oncol：一文掌握ROS-1阳性肺癌研究进展

2017-09-06

ms3117646317107274

#S-1#

Lancet Oncol:TAS-102 联合贝伐单抗有效治疗难治性转移性结直肠癌

2017-08-07

ms3117646317107274

#S-1#

Lancet Oncol：C-TASK FORCE研究：TAS-102 联合贝伐单抗有效治疗难治性转移性结直肠癌

2017-08-07

ms3117646317107274

#S-1#

Lancet Oncol：TAS-102+贝伐单抗可用于治疗难治性的转移性结直肠癌

2017-07-31

ms3117646317107274

#S-1#

NLS Pharma称NLS-1治疗成人ADHD患者的二期数据令人鼓舞

2017-06-09

ms3117646317107274

#S-1#

“饿死”癌细胞的药物IACS-10759已进入临床试验阶段

2016-10-29

ms3117646317107274

#S-1#

Lancet Oncol：骨肉瘤：术前化疗效果差，术后要不要加强化疗？(EURAMOS-1)

2016-09-10

ms3117646317107274

#S-1#

Neurology：缺血性卒中生理功能的检测：PROMIS 优于SIS-16量表

2016-07-12

ms3117646317107274

#S-1#

Lancet：胰腺癌术后辅助化疗，S-1不劣于吉西他滨

2016-06-04

ms3117646317107274

#S-1#

Lancet Oncol：可考虑将S-1作为HER2阴性的转移性乳腺癌的一线治疗方法

2015-11-25

ms3117646317107274

#S-1#

FDA批准TAS-102(Lonsurf)用于治疗晚期结直肠癌

2015-10-03

ms3117646317107274

#S-1#

NEJM：TAS-102对难治性转移性结直肠癌的临床效果

2015-05-16

ms3117646317107274

#S-1#

ASCO GI 2015：S-1/顺铂可作为晚期胃癌新辅助化疗方案（COMPASS研究）？

2015-01-23

ms3117646317107274

#S-1#

RECOURSE试验III期：TAS-102对比安慰剂治疗已给予更佳支持治疗且能耐受标准化疗的mCRC患者

2014-12-10

ms3117646317107274

#S-1#

CSMO 2014 ：S-1或为晚期非小细胞肺癌治疗新选择

2014-07-11

ms3117646317107274

#S-1#

北山丈二：S-1+DTX治疗腹膜播散胃癌

2014-07-05

ms3117646317107274

#S-1#

TAS-102能提高转移性结肠癌患者的存活率

2014-07-04

ms3117646317107274

#S-1#

Gynecol Oncol：吉非替尼联合S-1与卡铂一线治疗发生表皮生长因子受体突变的晚期非小细胞肺癌患者的II期临床试验

2014-06-27

ms3117646317107274

#S-1#

吉西他滨联合S-1对比吉西他滨联合顺铂治疗晚期胆管癌的随机III期研究：一项日本临床肿瘤研究组的新研究（JCOG1113）

2014-06-27